Avian metapneumovirus (AMPV) is a paramyxovirus that principally causes respiratory disease and egg production drops in turkeys and chickens. Together with its closely related human metapneumovirus (HMPV), they comprise the genus Metapneumovirus in the family Paramyxoviridae. Little is currently known about the mechanisms involved in the budding of metapneumovirus. By using AMPV as a model system, we showed that the matrix (M) protein by itself was insufficient to form virus-like-particles (VLPs). The incorporation of M into VLPs was shown to occur only when both the viral nucleoprotein (N) and the fusion (F) proteins were co-expressed. Furthermore, we provided evidence indicating that two YSKL and YAGL segments encoded within the M protein were not a functional late domain, and the endosomal sorting complex required for transport (ESCRT) machinery was not involved in metapneumovirus budding, consistent with a recent observation that human respiratory syncytial virus, closely related to HMPV, uses an ESCRT-independent budding mechanism. Taken together, these results suggest that metapneumovirus budding is independent of the ESCRT pathway and the minimal budding machinery described here will aid our future understanding of metapneumovirus assembly and egress.
INTRODUCTION
Avian metapneumovirus (AMPV) is a paramyxovirus that causes acute respiratory disease in turkeys. In recent years this virus has emerged as a major economic problem for the turkey industry worldwide (Catelli et al., 2006 (Catelli et al., , 2010 Easton et al., 2004; Govindarajan & Samal, 2004; Naylor et al., 2004 Naylor et al., , 2007 Njenga et al., 2003; Toquin et al., 2003 Toquin et al., , 2006 Velayudhan et al., 2005 Velayudhan et al., , 2008 . AMPV infection can also result in variable degrees of clinical illness in other avian species including chickens Njenga et al., 2003) . For AMPV, there are four subgroups, namely, A, B, C and D . Interestingly, sequence analysis has discovered that the AMPV subgroup C is more closely related to human metapneumovirus (HMPV) than to any other AMPV subgroup (Govindarajan & and cause respiratory symptoms (Velayudhan et al., 2006) . In addition, a recent evolutionary study of HMPV and AMPV led to a hypothesis that the human virus may have evolved from its avian counterpart and at some point was transmitted to humans (de Graaf et al., 2008) . These findings clearly demonstrate the necessity of a comparative study of these two viruses for the better understanding of molecular biology and pathogenesis of the metapneumovirus subgroup. In the paramyxovirus family, metapneumovirus is closely related to respiratory syncytial virus that infects both human and animals . Both groups of viruses are assigned to the subfamily Pneumovirinae of the family Paramyxoviridae.
The M protein of paramyxoviruses is the most abundant structural protein in the virion and the unique topological location of the M protein has helped create an assumption that M might be the primary driving force for paramyxovirus budding (Takimoto & Portner, 2004) . Paramyxoviruses such as Sendai virus (SeV) and human parainfluenza virus type 1 are able to release virus-like-particles (VLPs) with the expression of M alone (Ciancanelli & Basler, 2006; Coronel et al., 1999; Irie et al., 2007; Pantua et al., 2006; Patch et al., 2007) , while other paramyxoviruses including mumps and simian virus 5 (SV5) can only produce VLPs when M proteins are expressed in combination with other viral proteins (Li et al., 2009; Schmitt et al., 2002) . Recent studies of influenza A viral budding have also demonstrated that the M protein alone is insufficient to form VLPs (Chen et al., 2007; Wang et al., 2010a) .
M proteins of some already studied paramyxoviruses also encode a domain with late budding function, termed Ldomain, which is required for the efficient release of budding virions from the plasma membrane of infected cells (Chen & Lamb, 2008) . The L-domain is firstly identified in retroviral Gag proteins with three core motifs (PPxY, PT/SAP and YPXL, where x can be any amino acid), and it has been shown that interactions of L-domains with the endosomal sorting complex required for transport (ESCRT) machinery are critical to the completion of retroviral particle release and spread of infections Freed, 2002) . A study examining the budding requirements of SV5, the prototype of paramyxovirus, has identified a novel L-domain consisting of FPIV core sequence in the SV5 M protein necessary for viral budding (Schmitt et al., 2005) . Despite the L-domain peptide sequence being variable from that of retroviruses, SV5 utilizes ESCRT machinery to assist in viral budding (Schmitt et al., 2005) . Characterization of the budding requirements for other paramyxoviruses has yielded conflicting data. For example, early SeV VLP studies suggested that Alix [apoptosis-linked gene 2 (ALG-2)-interacting protein], a host protein involved in apoptosis and endosomal membrane trafficking, was required to promote VLPs release by interacting with either an YLDL L-domain in the M protein or the C protein (Irie et al., 2007) . However, a recent study provided the evidence suggesting that SeV budding, at least in the course of virus infection, was not sensitive to inhibition of the ESCRT pathway (Gosselin-Grenet et al., 2007) . In an effort to identify the L-domain in Nipah virus (NiV), one group reported on the identification of the YMYL sequence in the M protein as a functional L-domain (Ciancanelli & Basler, 2006) , whereas another study suggested that the YPLGVG segment in NiV M protein has a late budding function (Patch et al., 2008) . Compared to the well-studied retrovirus, little is known about the molecular mechanism and cellular machinery involved in paramyxovirus budding; however, there is growing evidence that some members of paramyxovirus bud through an ESCRT-independent pathway and such viruses include NiV and human respiratory syncytial virus (HRSV) (Patch et al., 2008; Utley et al., 2008; Wang et al., 2010b) .
To understand the mechanism of metapneumovirus assembly and release, we have in this study characterized the requirements for metapneumovirus budding by using the AMPV-C model system. Specifically, we addressed the following questions. What are the functional requirements for metapneumovirus budding? Does the M protein of metapneumovirus, like Ms in many enveloped viruses, play an important role in budding? Are two YSKL and YAGL sequences encoded within the M protein functional in inducing virus budding? Is the ESCRT pathway involved in metapneumovirus budding? The results of these studies identified the minimal budding machinery for metapneumovirus and revealed new fundamental information about the potential mechanism involved in metapneumovirus assembly and egress.
RESULTS
The M protein alone of AMPV-C is not sufficient to bud and form extracellular VLPs Initially, we asked whether the AMPV-C M protein alone can form VLPs. For this study, the pCAGGS vector containing a chicken b-actin promoter was used due to its capability of viral protein expression in a wide variety of systems (Chen et al., 2007; Irie et al., 2007; Li et al., 2009; Niwa et al., 1991; Schmitt et al., 2002) . A standardized viral budding assay was used in this study (Garrus et al., 2001; Jin et al., 2007; Li et al., 2002) . All cDNA expression clones encoding AMPV-C proteins were developed by regular RT-PCR and cloning cDNA procedures (Yu et al., 2010) (Fig. 1a) .
Transfection of 293T cells with increasing amounts of pM expression vector resulted in a dose-dependent expression of intracellular M proteins; however, none of the transfected cells produced VLPs (Fig. 1b) . In contrast, transfected 293T cells with as little as 0.5 mg of human immunodeficiency virus (HIV)-1 Gag plasmid gave rise to Gag particles. These results suggest that the AMPV-C M protein by itself is insufficient to bud into VLPs.
Requirements of viral N and F proteins for the incorporation of M into extracellular VLPs
The failure of AMPV-C M in forming extracellular VLPs is somewhat reminiscent of a VLP production defect previously reported for the M protein of SV5 (Schmitt et al., 2002) . The results of this study coupled with the fact that two viral envelope proteins (G and SH) can be deleted without substantially affecting growth kinetics of metapneumovirus in vitro (Biacchesi et al., 2004 (Biacchesi et al., , 2005 directed our focus to the potential involvement of viral F and N proteins. We asked whether co-expression of these two proteins was capable of instigating the competence of M protein budding into extracellular VLPs. To address this question, we generated AMPV-C N and F protein expression constructs (pN and pF) containing an inserted haemagglutinin (HA) epitope tag at the C terminus of either protein using the strategy described previously (Fig. 1a ).
Co-expression of both N and F proteins with the M protein efficiently generates extracellular M-containing VLPs (Fig. 1c) . Notably, M VLP production defect cannot be efficiently overcome by the presence of just one protein (N or F specifically), indicating that a co-operative action provided by N and F is needed to incorporate M into budding particles. The F protein (Fig. 1c) is probably a cleaved form responding to an F1 subunit (based on the molecular mass calculation). Also we found that N and F, when expressed alone or in combination, were able to be released into the culture medium independently of the expression of the M protein (data not shown). Secretion of the F protein has been reported previously in NiV when F was expressed alone (Patch et al., 2007) . The observation of M's inability in inducing VLP production in multiple experiments, coupled with the fact that VLP production by N and F are constantly demonstrated, suggests a primary role of these two proteins in driving AMPV-C virus particle production. This hypothesis clearly warrants future investigation.
To validate VLPs produced by co-expression of M/N/F proteins, we performed a density gradient analysis of VLPs made from this system (Patch et al., 2007) . The results showed that three proteins predominantly co-migrated in the no. 3 gradient fraction, indicating that they are packaged in the same particle (Fig. 2a) . Absence of the F protein in the no. 2 fraction or little M protein was detected in both no. 2 and no. 4 fractions may reflect variable expression levels of the respective proteins. Importantly, analysis of infectious virus particles produced by Vero cells under the same experimental conditions followed by probing with an anti-AMPV-C N protein mAb (Yu et al., 2006) revealed a similar pattern in which the majority of virus particles were associated with the no. 3 gradient fraction and less so with the no. 2 fraction and little with the no. 4 fraction (Fig. 2b) . The data further supported that VLPs generated by our co-expression system resemble authentic virus particles of AMPV-C in terms of particle density.
Involvement of putative L domains and the ESCRT pathway in AMPV-C budding
The M protein of AMPV-C encodes two putative L domains, YSKL and YAGL, which have been suggested previously for a role in directing viral budding (Munir & Kapur, 2003) . Bioinformatic analysis of N and F protein sequences did not enable us to identify any of the previously described L-domain motifs in these two proteins. YPXL-like domain with the late budding function is identified in a variety of viruses, including retroviruses and paramyxoviruses (Chen & Lamb, 2008; . With the minimal budding machinery we identified from the above experiments, we next asked whether these two putative L-domains are functional in AMPV-C budding. We were also interested in examining whether the ESCRT pathway, the well-defined budding mechanism for retrovirus and other enveloped RNA viruses (Chen & Lamb, 2008; , plays a role in AMPV-C budding.
To this end, three M mutants were generated in the pCAGEN vector. Two mutants termed M DL1 and M DL2 , contained an AAAA segment in substitution of YSKL and YAGL sequences in the native locations, respectively. The other mutant, termed M DL1/L2 , was created in which two putative L-domains, YSKL and YAGL, were changed to AAAA segments (Fig. 3a) . As demonstrated in Fig. 3(b) , similar levels of intracellular M protein expression were observed among cells transfected with the parental M and its derivatives, indicating that the substitutions did not substantially alter overall intracellular expression of the M proteins. Interestingly, none of these mutations disrupted M1 budding as similar amounts of VLPs were produced among wild-type (WT) M and its three mutants (Fig. 3b) . The results demonstrated that two putative L-domains are not functional in providing late budding function for AMPV-C budding at least in our experimental conditions. In a virus budding assay, extracellular VLPs are normally pelleted from transfected cells after 48 h, which may not allow for accurate measurement within a kinetic range. To potentially overcome this shortcoming, we modified our assay by collecting and pelleting extracellular VLPs at 24 and 36 h following transfection, and examined the budding efficiency of the double mutant M DL1/L2 in the presence of F and N proteins. Only at 36 h post-transfection (Fig. 3c) were both WT M and M DL1/L2 mutant incorporated into VLPs with an indistinguishable efficiency, further confirming that putative L-domains are dispensable in AMPV-C budding, particularly M incorporation to VLPs. Interestingly, we noticed that at 24 h post-transfection the N protein was the only protein budding out. This observation suggests that N may play an early role in the nucleating budding process, which clearly warrants further investigation.
We next determined whether the ESCRT pathway is involved in AMPV-C budding by taking advantage of a set of well-studied dominant-negative inhibitors that block retroviral Gag particle release by disrupting the ESCRT pathway by different mechanisms. These inhibitors include: (i) TSG-59, the N-terminal fragment of the tumour susceptibility gene 101 (Tsg101), which suppresses L-domain PTAP-dependent HIV-1 Gag particle release by binding the PTAP L-domain and blocking its function (Demirov et al., 2002; Goila-Gaur et al., 2003; Luttge et al., 2008; ShehuXhilaga et al., 2004) ; (ii) TSG-39, the C-terminal fragment of Tsg101, which inhibits HIV-1 Gag budding mediated by either L-domain PTAP or PPXY by globally disrupting the class E VPS pathway (Demirov et al., 2002; Goila-Gaur et al., 2003; Luttge et al., 2008; Shehu-Xhilaga et al., 2004) ; (iii) a fragment of Alix, composed of residues 364-716 (Alix 364-716), which blocks L-domain YPXL/LXXLF-dependent HIV-1 Gag particle production by inhibiting the recruitment of ALIX protein (Lee et al., 2007; Luttge et al., 2008; Munshi et al., 2007) ; (iv) an ATPase-deficient mutant of Vps4A (E228Q) that broadly blocks the pinch-off of many enveloped viruses that exclusively depend on the ESCRT pathway (Garrus et al., 2001) . TSG-59, TSG-39 and the Alix fragment were kindly provided by Eric Freed at National Cancer Institute, while Vps4A (E228Q) was a gift of W. Sundquist, University of Utah.
To examine the sensitivity of AMPV-C VLPs release to overexpression of these dominant-negative budding inhibitors, we transfected 293T cells expressing triple plasmids (M, N and F) with plasmids expressing TSG-59, TSG-39, Alix 364-716 or Vps4A (E228Q). Their effects on VLP production were determined by a virus budding assay (Fig.  4) . As a positive control, inhibition of HIV-1 Gag particle release by TSG-39 or Vps4A (E228Q) expression was also tested. For quantification of specific protein levels, protein bands that were visualized in Western blots were scanned into a computer and analysed by using IMAGEQUANT software (NIH). The relative virus release efficiency was calculated as the ratio of VLP-associated viral proteins to total viral proteins (cell plus VLP).
As reported previously (Demirov et al., 2002; Garrus et al., 2001; Goila-Gaur et al., 2003; Luttge et al., 2008) , expression of both TSG-39 and Vps4A (E228Q) greatly inhibited HIV-1 Gag release, confirming that our assay conditions can effectively measure virus budding requiring the ESCRT pathway (Fig. 4a) . For example, overexpression of these inhibitors significantly reduced HIV-1 Gag particle release and the inhibition rate ranged from 50 to 70 % compared with untreated controls. In contrast, AMPV-C VLPs release was not inhibited under the assay conditions as amounts of VLPs were basically identical between treated and untreated samples (Fig. 4b) . The data collectively suggests that the ESCRT pathway is not involved in AMPV-C VLP release.
DISCUSSION
In the present study, we have characterized the budding machinery of AMPV-C. Our result on the inability of AMPV-C M protein in forming extracellular VLPs clearly places AMPV-C, likely metapneumoviruses, into a specialized group of paramyxoviruses (also containing mumps virus and SV5) whose viral M proteins alone are insufficient to form VLPs (Li et al., 2009; Schmitt et al., 2002) . Also similar to this group of viruses, the M protein of AMPV-C can be efficiently incorporated into extracellular VLPs by co-expression of its N and F proteins.
During the course of our work, we noticed that two putative L-domains within the AMPV-C M protein are not authentic L-domains in the promotion of VLP release. This discovery is further substantiated by evidence showing that AMPV-C VLP budding is insensitive to inhibition by specific dominant-negative inhibitors that block L-domain functions and the ESCRT protein network. It should be noted that all dominant-negative inhibitor proteins used in this study are derived from human cells, while AMPV-C is a virus that infects poultry. Due to host specificity and speciation of certain proteins (both cellular and viral) within any system, the potential for poor interaction between the two aforementioned proteins remains. The human protein-derived inhibitors we used however have been successfully shown to suppress the budding function of L-domains from viruses that infect chicken, horses and cats ( , 2004) . This evidence, when coupled with the fact that these proteins are involved in ECSRT machinery and are remarkably conserved amongst different species (Chen & Lamb, 2008; Morita & Sundquist, 2004) , allow us to postulate that the protein inhibitors from humans are likely to be effective in blocking non-human viruses that employ the ESCRT pathway for their particle budding and egress. Thus, based on our data we conclude that AMPV-C may utilize a budding mechanism different from that of retroviruses and many RNA-enveloped viruses, depending Fig. 4 . The ESCRT pathway is not involved in AMPV-C budding. VLPs production by HIV-1 Gag expression vector in the absence and presence of 39 Tsg101 or Vps4A (E228Q) protein served as a control to validate viral budding assay (a). Western blotting procedure as described in Methods was used to analyse Gag protein expression and Gag VLP production probed by HIV-Ig (NIH AIDS Research and Reference Program). AMPV-C VLP production was derived from 293T cells transfected with three expression plasmids (M, N and F), either with or without each of the dominant-negative inhibitors as indicated (b). At 36 h post-transfection, VLPs and cell lysates were analysed in Western blot with anti-HA mAb. Viral protein levels were quantified by ImageJ software (http://rsbweb.nih.gov/ij/), and the VLP release efficiency for AMPV-C or HIV-1 Gag was calculated as the ratio of VLP-associated proteins to total viral proteins (cell plus VLP), and the results represent means from at least three independent experiments. Error bars indicate SD. Note that the Vps4A (E228Q) and HIV-1 Gag or AMPV-C M/N/F VLP data were obtained from different experiments under similar experimental conditions, and have been placed together arbitrarily according to their migration positions in the gel.
on which L-domains are in concert with the ESCRT pathway (Chen & Lamb, 2008; Morita & Sundquist, 2004) .
The family Paramyxoviridae contains viruses with different genetic backgrounds that induce a wide range of distinct clinical illnesses in humans and animals (Knipe et al., 2001 ). This divergence is also reflected in the L-domains and associated cellular pathways that paramyxoviruses utilize for their budding. Several studies have shown that several paramyxoviruses including SV5, SeV and NiV possess L-domains (Ciancanelli & Basler, 2006; Irie et al., 2007; Patch et al., 2008; Schmitt et al., 2002) . Despite sequence variations, these L-domains interact with various components of the ESCRT machinery to promote virus budding. However, in contrast to these paramyxoviruses, a recent study has provided direct evidence that HRSV does not encode an L-domain, and this virus utilizes a Rab11 pathway for virus budding instead of ESCRT machinery (Utley et al., 2008) . It is worthwhile mentioning that in addition to HRSV, influenza A virus and alphavirus budding are also insensitive to inhibition by dominantnegative Vps4 inhibitors (Bruce et al., 2010; Chen et al., 2007; Taylor et al., 2007) . Involvement of the Rab11 pathway has been established in a recent paper (Bruce et al., 2010) for influenza A virus budding and filament formation. Considering a close genetic relatedness between metapneumovirus and RSV, it will be interesting to examine whether the Rab11 pathway is involved in AMPV-C virus budding. Regardless of the mechanism concerning how AMPV-C buds, the results presented in this study highlights the many diversified strategies viruses employ for their budding that have been previously unappreciated. This study represents the first step in defining viral proteins and host cell machinery required for metapenmovirus assembly and budding.
METHODS
Plasmids. PCR and cloning were performed with proof-reading Vent DNA polymerase (New England Biolabs) under standard reaction conditions and the integrity of all PCR-derived DNA fragments were verified by sequencing. All primers and sequences are available from the authors upon request. For the expression of AMPV-C viral proteins that were used in viral budding assay, cDNA sequences encoding N, P and M of AMPV-C were individually amplified from a pLF-2.1 plasmid (containing AMPV-C genome except for L-trailer-59 sequence) (Yu et al., 2010) by PCR, and subcloned into the eukaryotic expression vector pCAGEN (Addgene plasmid 11160; Addgene) to generate pCAG-N, pCAG-P and pCAG-M, respectively. To facilitate the detection of protein expression, an HA epitope tag was placed at the C terminus of viral proteins. To study the functions of the two putative L-domains within the M protein in AMPV-C budding, we replaced the YSKL or YAGL sequence with a sequence of AAAA residues and these two substitution constructs were named pCAG-M DL1 and pCAG-M DL2 , respectively. An additional M mutant, designated pCAG-M DL1/DL1 , was generated in which both YSKL and YAGL motifs were simultaneously mutated to the AAAA segment. A pHIV-1 Gag plasmid that expresses HIV-1 Gag precursor with HA tag at the C terminus was used as a control in viral budding assay.
Plasmids encoding GFP-tagged ATP hydrolysis-deficient Vps4A E228Q mutant (Vps4Awt and Vps4AEQ) were kindly provided by W. Sundquist (University of Utah, USA). HA-tagged derivatives of Tsg101, TSG-59 and TSG-39 in the pcGNM2 expression vector, were gifts of Z. Sun (Stanford University, USA) through Eric Freed (National Cancer Institute at Frederick, Frederick, MD, USA). Expression vector for the V-domain of hAlix (residues 364-716) was kindly provided by Eric Freed (National Cancer Institute at Frederick, Frederick, MD, USA).
Cells and antibodies. 293T, HeLa, COS-1 and Vero cells were cultured in Dulbecco's minimal essential medium supplemented with 10 % FBS. mAb against the HA epitope was purchased from SigmaAldrich. Polyclonal rabbit anti-GFP was obtained from Santa Cruz Biotechnology. Secondary antibodies such as donkey anti-rabbit IgG-HRP, goat anti-mouse IgG-HRP and goat anti-human IgG-HRP were purchased from Abcam. Human immunoglobulin from HIV-1-infected patients (HIV-Ig) was obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID. Mouse anti-AMPV N protein mAb was described in our previous publication (Yu et al., 2006) . Viral budding assay. 293T cells or other cells grown in 60 nm plates were transfected with the following amounts of plasmid DNA: 2.0 mg pCAG-M, alone or with 1 mg pCAG-N or pCAG-F, or with a combination of pCAG-N and pCAG-F (1 mg each plasmid). The total amount of transfected DNA in each sample was held constant using an empty vector lacking a coding region to compensate for any variations. Transfection was performed by using TransIT-LT1 (Mirus) following the procedure outlined by the manufacturer. For the preparation of VLPs, at 48 h after transfection, the culture medium was harvested and pelleted by centrifugation at 2000 g for 10 min. The clarified supernatants were firstly passed through a 0.22 mm filter before being layered onto a 20 % sucrose cushion (PBS) and centrifuged at 100 000 g for 2 h at 4 uC in a Beckman Ti rotor (Beckman Coulter). The resuspension of pellet followed by low-speed centrifugation were subject to further analysis as VLPs. For the preparation of cell lysates, at 48 h post-transfection, cells were harvested and lysed in the lysis buffer (25 mM Tris/HCl, pH 8.0, 150 mM NaCl, 1 % deoxycholic acid, 1 % Triton X-100) in the presence of 16 protease inhibitor cocktail (Pierce). The cell lysates were prepared by the removal of nuclei by centrifugation at 2000 g at 4 uC for 10 min. VLPs and cell lysates were separated on a 12 % SDS-PAGE and transferred to a nitrocellulose membrane (Pierce) followed by blocking in PBS buffer containing 0.5 % Tween-20 and 5 % dry milk powder. Viral proteins were detected by standard Western blotting procedure coupled with the ECL system (Pierce) with appropriate primary and secondary antibodies as described above. The same procedure was also performed to analyse VLPs production by HIV-1 Gag and to characterize the effects of dominant-negative inhibitors targeting the ESCRT pathway on the budding of AMPV-C and HIV-1 Gag, respectively.
Density gradient analysis of VLPs and infectious virus particles. 293T cells were transfected with expression plasmids (M, N and F) as described above. At 72 h post-transfection, culture medium was collected, clarified and filtered, and then centrifuged through a 20 % sucrose cushion (w/v) in PBS at 100 000 g for 2 h at 4 uC. Density gradient analysis of VLPs upon co-expression of M, N and F proteins was performed according to a protocol developed by Patch et al. (2007) . Briefly, the resulting pellet collected from the above centrifugation of 20 % sucrose cushion was resuspended in PBS and clarified supernatants were then loaded directly onto the top of a continuous sucrose gradient of 5-50 % sucrose. The gradient was centrifuged in a SW41 rotor at 100 000 g for 16 h at 4 uC. Fractions (1.0 ml) were collected from the top and each fraction was then pelleted through a 20 % sucrose cushion (w/v) in PBS at 100 000 g for 2 h at 4 uC. Resuspended pellets corresponding to each fraction were analysed in SDS-PAGE/Western blotting assay as described above. The same density gradient analysis protocol was used to characterize infectious virus particles generated by Vero cells infected with AMPV-C and Western blotting assay was probed with mouse anti-N mAb.
